Niacin for Lipids: What the Evidence Says (Plus How It Compares to Statins and Ezetimibe)

What Is Niacin and Why Was It Used for Lipids?

Niacin is vitamin B3 in its pharmacologic form, nicotinic acid. At the gram-level doses used in lipid therapy (1 to 3 g per day), it acts through GPR109A receptors in adipose tissue to suppress free fatty acid mobilization, ultimately reducing hepatic VLDL synthesis. The lipid changes that follow are broad: HDL rises, triglycerides fall substantially, LDL falls moderately, and lipoprotein(a) may also decrease by 20 to 30% [1].

Niacin's story in cardiology begins in the 1970s. The Coronary Drug Project, which enrolled 8,341 men with prior myocardial infarction, showed that niacin (3 g/day) reduced nonfatal MI by 26% compared with placebo over five years [2]. That finding, combined with niacin's unique ability to raise HDL more than any other drug, made it a cornerstone of lipid practice for three decades.

Then statins arrived. The introduction of lovastatin in 1987 and later atorvastatin (Lipitor), rosuvastatin (Crestor), and simvastatin (Zocor) delivered 40 to 60% LDL reductions with cardiovascular outcome data no other drug class could match. Niacin's role shifted to adjunctive therapy, primarily aimed at raising HDL when statins alone left it low. Two large trials then tested that exact hypothesis. Both failed.

How Niacin Compares With Statins on Lipid Numbers

Statins reduce LDL through a different and more potent mechanism: inhibition of HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The LDL reductions achieved by individual agents vary considerably:

Atorvastatin (Lipitor): 10 mg reduces LDL by approximately 37%; 80 mg reduces it by roughly 51% [3]. The ASCOT-LLA trial (N=10,305) showed that atorvastatin 10 mg lowered the primary endpoint (nonfatal MI plus fatal coronary heart disease) by 36% (P<0.0001) versus placebo in hypertensive patients [4].

Rosuvastatin (Crestor): 10 mg reduces LDL by about 46%; 40 mg by approximately 55%, making it the most potent statin per milligram. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the primary MACE endpoint by 44% in patients with elevated CRP but normal LDL [5].

Simvastatin (Zocor): 20 to 40 mg reduces LDL by 35 to 41%. The Heart Protection Study (N=20,536) showed simvastatin 40 mg reduced major vascular events by 24% over five years across a wide range of baseline LDL levels [6].

Niacin monotherapy at 2 g/day reduces LDL by only 10 to 15%. Head-to-head, no statin alternative exists for pure LDL lowering. Niacin's comparative advantage, if any, lies in raising HDL and lowering triglycerides, which statins accomplish only modestly.

The AIM-HIGH and HPS2-THRIVE Trials: Why Niacin Lost Its Adjunctive Role

These two trials are the reason contemporary guidelines deprioritize niacin.

AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) enrolled 3,414 patients with established cardiovascular disease, low HDL, and elevated triglycerides. All patients received simvastatin (plus ezetimibe if needed) to keep LDL between 40 to 80 mg/dL. Half also received extended-release niacin 1,500, 2 to 000 mg/day. After 36 months the trial was stopped early for futility: niacin added zero reduction in the primary endpoint (composite of coronary death, nonfatal MI, ischemic stroke, hospitalization for acute coronary syndrome, or symptom-driven coronary or cerebral revascularization). The niacin arm actually showed a non-significant trend toward more ischemic strokes [7].

HPS2-THRIVE (Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events) was larger still: 25,673 patients with atherosclerotic disease randomized to extended-release niacin 2 g plus laropiprant (a flushing suppressant) versus placebo, on top of statin therapy. After 3.9 years, the primary composite showed no significant reduction (rate ratio 0.96 to 95% CI 0.90, 1.03, P=0.29). Worse, serious adverse events, including new-onset diabetes, gastrointestinal bleeding, infection, and musculoskeletal problems, were significantly more frequent in the niacin group [8].

The investigators' own conclusion, published in the New England Journal of Medicine: "There was no significant difference between the niacin-laropiprant group and the placebo group in the incidence of major vascular events." This outcome prompted the FDA to withdraw approval of the fixed-dose combination products Advicor (niacin/lovastatin) and Simcor (niacin/simvastatin) in 2016 [9].

Ezetimibe (Zetia): The Better LDL Add-On

After statin therapy, ezetimibe is now the preferred second-line LDL-lowering agent for most patients according to the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction [10]. It inhibits the NPC1L1 transporter in the small intestine, blocking dietary and biliary cholesterol absorption.

The IMPROVE-IT trial (N=18,144) compared simvastatin 40 mg alone versus simvastatin 40 mg plus ezetimibe 10 mg in patients stabilized after an acute coronary syndrome. The combination reached a time-averaged LDL of 53.7 mg/dL versus 69.5 mg/dL for monotherapy. At seven years, the primary MACE endpoint was 32.7% in the combination arm versus 34.7% with simvastatin alone (HR 0.936 to 95% CI 0.89, 0.99, P=0.016) [11]. Modest but real. The tolerability profile of ezetimibe is excellent, with a side-effect rate indistinguishable from placebo in most trials.

Compared with niacin, ezetimibe offers:

• A 5 to 6% absolute MACE reduction proven in a large outcome trial.
• No flushing, no hyperglycemia signal, no hepatotoxicity concern.
• Once-daily 10 mg dosing with no titration required.
• Generic availability since 2017, making cost a diminishing barrier.

Niacin does something ezetimibe cannot: raise HDL meaningfully. Whether that HDL elevation translates to clinical benefit now appears, based on AIM-HIGH and HPS2-THRIVE, to be a no, at least in statin-treated patients.

Niacin Dosing, Formulations, and the Flushing Problem

Three formulations have been used clinically:

1. Immediate-release (IR) niacin: taken two to three times daily with meals. Flushing is intense and peaks 20 to 30 minutes post-dose. Most cardiologists now avoid IR niacin except in specialist practices for severe combined dyslipidemia.

2. Extended-release (ER) niacin (Niaspan): once-nightly dosing, 500 mg titrated monthly to a target of 1,000, 2 to 000 mg. Flushing is reduced but still reported by up to 70 to 80% of patients at therapeutic doses [12]. Aspirin 325 mg taken 30 minutes before the dose blunts flushing via COX-1 inhibition of prostaglandin D2 release [13].

3. Sustained-release (SR) niacin: intermediate flushing but higher hepatotoxicity risk. Generally avoided.

Standard titration for ER niacin:

• Weeks 1, 4: 500 mg at bedtime.
• Weeks 5, 8: 1 to 000 mg at bedtime.
• Week 9 onward: 1,500, 2 to 000 mg at bedtime, as tolerated.

Liver function tests and fasting glucose should be checked at baseline and at 12 weeks. The hepatotoxicity risk is modest with ER niacin at doses at or below 2 g/day, but SR formulations at equivalent doses carry a substantially higher transaminase elevation rate.

Who Might Still Use Niacin in 2025?

Niacin is not entirely abandoned. A narrow set of patients may still receive it:

Severe hypertriglyceridemia (triglycerides above 500, 1 to 000 mg/dL). The primary risk here is pancreatitis, not MACE. Fibrates are first-line, but niacin may be added when fibrates alone cannot control levels. The ACC/AHA note this as an acceptable use even in their most recent cholesterol guidelines [10].

Isolated low HDL with high triglycerides when statins and fibrates are insufficient. The clinical benefit of correcting this pattern remains unproven, but some specialists accept it as a reasonable risk-benefit trade in selected very high-risk patients.

Lipoprotein(a) elevation. Niacin reduces Lp(a) by 20 to 30%, and elevated Lp(a) is an independent cardiovascular risk factor [14]. No dedicated outcome trial for niacin on Lp(a) endpoints exists; this remains a theoretical indication while RNA-targeted therapies (pelacarsen, olpasiran) advance in trials.

Statin intolerance with residual LDL/TG burden. In patients who cannot tolerate any statin and for whom ezetimibe is insufficient, niacin remains a licensed option, though PCSK9 inhibitors (evolocumab, alirocumab) are now preferred.

Niacin vs. Atorvastatin, Rosuvastatin, Simvastatin, and Ezetimibe: A Clinical Decision Framework

The following decision framework is based on the 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [15] and the 2022 cholesterol update [10], synthesized with the outcomes of AIM-HIGH, HPS2-THRIVE, JUPITER, ASCOT-LLA, IMPROVE-IT, and Heart Protection Study.

Step 1. Establish baseline LDL-C goal by risk tier.

• Very high risk (ASCVD event history): LDL <55 mg/dL.
• High risk (10-year ASCVD risk above 20%): LDL <70 mg/dL.
• Intermediate risk (7.5 to 20% 10-year risk): LDL <100 mg/dL.
• Low risk (<7.5% 10-year risk): LDL <130 mg/dL.

Step 2. Start high-intensity statin monotherapy for very-high and high-risk patients. High-intensity regimens (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) reduce LDL by at least 50%. Simvastatin 40 mg is a moderate-intensity option, though the FDA cap of 80 mg simvastatin for most patients (due to myopathy data) limits its ceiling [16].

Step 3. If LDL goal is not achieved on maximum-tolerated statin, add ezetimibe 10 mg. IMPROVE-IT demonstrated a 6.4% relative MACE reduction over seven years with this strategy [11].

Step 4. If LDL remains above goal, consider PCSK9 inhibition. Evolocumab (Repatha) and alirocumab (Praluent) lower LDL by an additional 50 to 60% on top of statin plus ezetimibe in FOURIER and ODYSSEY OUTCOMES, respectively.

Step 5. For residual hypertriglyceridemia above 500 mg/dL despite the above, add fenofibrate or icosapentaenoic acid (Vascepa 4 g/day), not niacin. REDUCE-IT (N=8,179) showed icosapentaenoic acid 4 g/day reduced MACE by 25% in statin-treated patients with elevated triglycerides and high cardiovascular risk [17].

Niacin enters consideration only at Step 4 or 5 in patients with isolated Lp(a) elevation awaiting RNA-based therapies, or when triglycerides remain above 500 mg/dL despite fenofibrate and icosapentaenoic acid.

Safety Monitoring for Patients Still on Niacin

Despite limited cardiovascular utility, some patients remain on niacin prescribed before 2014. Clinicians should assess:

Glycemia. Niacin raises fasting glucose by 5 to 10 mg/dL on average and increases new-onset diabetes risk. HPS2-THRIVE showed a 32% relative increase in new diabetes diagnoses in the niacin-laropiprant arm [8]. Check HbA1c at baseline and every 6 months.

Liver enzymes. Obtain ALT/AST at baseline, 12 weeks, and annually. Dose reduction or discontinuation if transaminases exceed three times the upper limit of normal.

Uric acid. Niacin raises serum urate by blocking tubular secretion. Patients with gout or hyperuricemia need baseline and periodic uric acid monitoring.

Drug interactions. Combining niacin with statins increases myopathy risk modestly, though the absolute rate remains low at doses below 2 g/day. The FDA withdrew Simcor partly because the combination offered no cardiovascular benefit while retaining this interaction risk [9].

Flushing management checklist:

• Take ER niacin at bedtime with a low-fat snack.
• Aspirin 325 mg (or ibuprofen 200 mg) 30 minutes before the dose.
• Avoid hot beverages and alcohol within two hours of dosing.
• Flushing typically diminishes after four to six weeks of consistent dosing.

The Coronary Drug Project Legacy: Why Earlier Data Looked Promising

The Coronary Drug Project's 15-year follow-up, published in 1986, showed that niacin-treated men had 11% lower all-cause mortality than the placebo group, even though niacin had been stopped years earlier [2]. That "legacy effect" generated enormous enthusiasm for niacin through the 1990s and early 2000s.

Two contextual points explain the discrepancy with modern trials. First, Coronary Drug Project participants received no statin therapy. Niacin was being compared to placebo without background LDL control, a completely different comparator environment. Second, baseline LDL levels were much higher: the trial predates widespread statin use, so the absolute room for any lipid-lowering agent to show benefit was larger. AIM-HIGH and HPS2-THRIVE added niacin to already-optimized statin regimens. In that setting, HDL-raising alone produced no incremental benefit, a finding consistent with Mendelian randomization studies showing that genetically elevated HDL does not reduce coronary disease risk [18].

The 2022 ACC/AHA guideline explicitly states: "Niacin is not recommended to further reduce cardiovascular risk in patients on statin therapy given lack of benefit and potential for harm" [10].

Practical Prescribing Reference

For clinicians who do prescribe niacin in the narrow indications above, Niaspan (ER niacin) remains FDA-approved and generically available. The prescribing information (FDA NDA 020381) specifies the following contraindications [19]:

• Active liver disease or unexplained persistent transaminase elevations.
• Active peptic ulcer disease.
• Arterial bleeding.

Relative contraindications in the labeling include poorly controlled diabetes, gout, and pregnancy. The 2021 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction notes that niacin's use "should be limited to patients with triglyceride-related pancreatitis risk or severe mixed dyslipidemia refractory to other agents" [10].

Starting dose for triglyceride lowering: 500 mg ER niacin nightly, titrated by 500 mg every four weeks to a maximum of 2 to 000 mg nightly. Expect a 4 to 6 week lag before triglyceride response is measurable.